Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363181 · ClinicalTrials.gov registry record
Side Effects of Antipsychotic Medications
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 76
- Enrollment target
NCT00363181: Completed study, sponsored by Stanford University.
NCT00363181 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00363181 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine directly slows down insulin secretion from the pancreas, thereby increasing the risk of developing diabetes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-12 |
What the finished NCT00363181 record still lists
NCT00363181 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00363181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00363181 about?
NCT00363181 is a clinical study titled "Side Effects of Antipsychotic Medications". Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine d...
What is the current status of trial NCT00363181?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2006-04. Estimated completion is 2011-12.
Who is sponsoring clinical trial NCT00363181?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia